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Abstract
The FAST project (Food Allergy Specific Immunotherapy) aims at the development of safe and effective treatment
of food allergies, targeting prevalent, persistent and severe allergy to fish and peach. Classical allergen-specific
immunotherapy (SIT), using subcutaneous injections with aqueous food extracts may be effective but has proven
to be accompanied by too many anaphylactic side-effects. FAST aims to develop a safe alternative by replacing
food extracts with hypoallergenic recombinant major allergens as the active ingredients of SIT. Both severe fish and
peach allergy are caused by a single major allergen, parvalbumin (Cyp c 1) and lipid transfer protein (Pru p 3),
respectively. Two approaches are being evaluated for achieving hypoallergenicity, i.e. site-directed mutagenesis and
chemical modification. The most promising hypoallergens will be produced under GMP conditions. After pre-
clinical testing (toxicology testing and efficacy in mouse models), SCIT with alum-absorbed hypoallergens will be
evaluated in phase I/IIa and IIb randomized double-blind placebo-controlled (DBPC) clinical trials, with the DBPC
food challenge as primary read-out. To understand the underlying immune mechanisms in depth serological and
cellular immune analyses will be performed, allowing identification of novel biomarkers for monitoring treatment
efficacy. FAST aims at improving the quality of life of food allergic patients by providing a safe and effective
treatment that will significantly lower their threshold for fish or peach intake, thereby decreasing their anxiety and
dependence on rescue medication.
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Introduction
Although reliable figures are still largely unavailable,
IgE-mediated food hypersensitivity (hereafter referred to
as food allergy) is thought to affect around 1-2% of
adults and 4-8% of children, i.e. roughly around 10 mil-
lion EU inhabitants (reviewed in [1,2]). Recent studies
within the FP6-funded project EuroPrevall [3] showed
tree nuts (hazelnut and walnut), fruits (apple, peach and
kiwi) and peanut are the most common plant foods
causing food allergy, followed by vegetables like carrot,
tomato and celery. After milk and egg, fish and shrimp
are most frequently causing food allergy to animal-
derived foods (pers. comm. M. Fernandez-Rivas).
The clinical presentation of food allergy varies from
mild local symptoms of the oral cavity, usually referred
to as the oral allergy syndrome (OAS), to severe sys-
temic reactions which can include life-threatening ana-
phylaxis. In the U.S., food-induced anaphylaxis is
* Correspondence: l.zuidmeer@amc.uva.nl
1Department of Experimental Immunology, Academic Medical Center,
Amsterdam, The Netherlands
Full list of author information is available at the end of the article
Zuidmeer-Jongejan et al. Clinical and Translational Allergy 2012, 2:5
http://www.ctajournal.com/content/2/1/5
© 2012 Zuidmeer-Jongejan et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
estimated to cause about 120,000 emergency room visits
and 3000 hospitalizations each year [4].
The only available treatment for food allergy is avoid-
ance, in conjunction with rescue medication in case of
accidental exposure. However, hidden allergens in com-
posite foods, unwanted contaminations and occasional
poor adherence to dietary restrictions make avoidance
difficult and ineffective. Therefore there is an urgent
need to develop a treatment for food allergy that lowers
the threshold significantly and makes avoidance less
stringent. Allergen-specific immunotherapy (SIT) is the
only treatment available that targets the immunological
cause of the disease. It has proven successful in treat-
ment of insect venom allergies and for respiratory aller-
gies such as rhino-conjunctivitis and asthma to pollen
and house dust mite [5-7], but due to the duration and
invasiveness (i.e. 3-5 years of monthly subcutaneous
injections) and the risk of anaphylactic side-effects, SIT
is a niche treatment compared to symptomatic drugs,
though new alternative routes have been recently suc-
cessfully explored [8].
Over the past decades, major inhalant and food aller-
gens have been identified, purified, cloned and pro-
duced as recombinant proteins. The use of
recombinant allergens to replace biological extracts
will contribute to enhance the efficacy of SIT by better
control over the dosage and elimination of some of the
disadvantages (variability in product quality, difficulty
in standardization of extracts, sensitization to new
allergens) inherent to biological extracts (reviewed in
[9]). The first clinical trials using recombinant aller-
gens of birch, grass and ragweed pollen have demon-
strated that single recombinant proteins can effectively
replace extracts [10,11].
For the development of immunotherapy for food
allergy, most attention has so far been given to peanut
egg and milk, as these foods are important causes of
severe food allergy, mainly in children. Oral immu-
notherapy approaches for several foods (milk, egg, pea-
nut) show desensitization but no tolerance and
commonly have side-effects (well-reviewed in [8]). As
children with transient milk or egg allergy seem to have
IgE primarily directed to conformational epitopes, sensi-
tive to heat or processing [12,13], two clinical trials
focused on investigating tolerance to heated milk and
egg products in this population [14,15]. Preliminary stu-
dies suggested accelerated tolerance induction, so a fol-
low-up study is ongoing. Subcutaneous allergen-specific
immunotherapy (SCIT) as a treatment for peanut allergy
has been evaluated using aqueous peanut extract.
Although a significant level of efficacy was demon-
strated, anaphylactic side-effects, caused by IgE-binding
to the injected allergen, were too frequent and the pro-
ject was abandoned [16,17]. In recent years, sublingual
therapy has gained a considerable share of the market
for the treatment of respiratory allergies in the form of
extract-based drops or tablets. Side-effects are reported
to be minimal and efficacy has been demonstrated. The
first reports of SLIT with food allergens, date from
2003, in kiwi [18,19]. More recently, SLIT using hazel-
nut [20,21] and peanut extract [22] has been reported
for the treatment of hazelnut and peanut allergy and
peach peel extract enriched for LTP was used in a SLIT
trial to treat peach allergy [23,24]. These treatments
resulted in a significant but moderately increased toler-
ated dose and systemic side-effects have so far rarely
been reported. Despite these quite promising results, in
FAST we have decided to target SCIT, the main reason
for this being the expected higher efficacy and better
compliance and safety, facilitated by performing treat-
ment in an outpatient clinical environment.
To increase safety and develop effective SCIT for the
treatment of food allergy, the allergen can be modified
in such way that it exhibits significantly decreased IgE-
binding potency, i.e. that it becomes hypoallergenic, but
retains T-cell reactivity. In addition, these hypoallergens
can be absorbed to aluminium hydroxide, which
increases safety due to its depot effect and furthermore
increases efficacy by its adjuvant effect.
There is still some disagreement concerning the
immunological basis of the beneficial effect of immu-
notherapy. Allergic patients can typically be distin-
guished from healthy subjects by the presence of
allergen-specific IgE antibodies, but a (usually not
observed) decrease in specific IgE can not explain the
beneficial effect of SIT. The current knowledge on the
characteristics of the allergic immune response and its
modulation by SIT has developed dramatically beyond
the level of serum IgE antibodies, in particular knowl-
edge on other isotypes such as IgG4 and IgA, on various
subsets of helper T-cells (Th-cells) and on the role of
innate antigen presenting cells (like dendritic cells
(DCs). Essentially there are two extremes for explaining
the beneficial effect of SIT: inhibition of allergic reac-
tions by blocking IgG4 and IgA antibodies or by a shift
from Th2 to Th1/Treg. FAST aims at induction of both
using hypoallergenic but immunogenic recombinant
allergens. Although double-blind placebo-controlled
food challenge (DBPCFC) will always remain the pri-
mary read-out for establishing efficacy, it is not an
appropriate tool to use at many (early) time-points dur-
ing treatment. However, reliable early (composite) bio-
markers for efficacy that correlate with the outcome of
the DBPCFC are not (yet) available. To improve and
identify relevant (composite) biomarkers for monitoring
efficacy of immunotherapy it is important to further
unravel the mechanism of protection in patients
responding favorably to immunotherapy. In depth
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monitoring of humoral and cellular immune parameters
will help identify such (early) biomarkers for efficacy.
Within this context it is the objective of the EU-
funded collaborative project FAST to develop a safe and
effective immunotherapy against persistent and life-
threatening food allergies. The project includes 15 part-
ners from 11 different countries. To address all the
main objectives indicated above, the partnership first
focuses on producing and testing a number of different
mutant (hypo-) allergens (and wild-type allergens for
comparison). Additionally, there are three companies,
two partners from the pharmaceutical industry (BIAL,
Spain and HAL Allergy, The Netherlands) and one bio-
tech company (BIOMAY, Austria) that will focus on the
production of the chosen hypoallergens under good
manufacturing practice (GMP) for the clinical trials. In
the consortium there are six clinical centers participat-
ing in six countries, chosen on the basis of expertise
and geographic background. Lastly, allergen-specific
MHC class II tertramers/multimers will be developed as
well as mouse models for immunotherapy with
hypoallergens.
The allergens
Ninety percent of all food allergies are caused by ± 10
foods. Allergy to some of these foods i.e. milk and egg,
are outgrown in the vast majority (milk) or up to 50%
(egg) of children before the age of five. Although these
are certainly relevant, persistent food allergies that stay
throughout adulthood perhaps represent a more impor-
tant target for developing immunotherapy (IT). Most
attention for the development of IT for food allergy has
so far been given to peanut and despite being usually
outgrown, also to egg and milk. Apart from prevalence,
the main reason for this focus is high risk of severe
reactions induced by these foods. Allergy to fruits, like
peach, and to tree nuts, fish and shrimp are also high
on the list of candidates to develop novel therapies:
allergy against these foods is prevalent, persistent and
potentially life-threatening and avoidance negatively
affects a healthy diet. For the development of a new
concept for the treatment of severe persistent food aller-
gies based on recombinant hypoallergens, the best pro-
spects for reaching clinical testing at Phase IIb level
within the life-time of an EU project are treatments tar-
geting food allergies that are dominated by a single
major allergen. As described above, in the case of severe
allergies to peanut but also to tree nuts there are at
least three major allergens, so multiple recombinant
allergens would be needed. Therefore, in the FAST pro-
ject we target two foods, one from animal origin, fish,
and one from plant origin, peach. Severe reactions to
fish and peach are both linked to a single dominant
allergen, parvalbumin (Cyp c 1/Gad c 1) and lipid
transfer protein (Pru p 3) respectively. Peach was chosen
as a representative of all fruit allergies linked to lipid
transfer protein. Both the natural and recombinant wild-
type (WT) are compared to hypoallergenic variants pro-
duced in FAST.
Two ways of rendering allergens hypoallergenic are
used in FAST. Recombinant technology allows modifica-
tion by site-directed mutagenesis and with this method
hypoallergenic mutants have been successfully developed
for several food allergens. These include the major pea-
nut allergens Ara h 1, 2 and 3 [25], the major fish aller-
gen Cyp c 1 [26,27] and the major fruit allergen Pru p 3
([28] and own observation). Another approach is chemi-
cal modification. Since the 1970s, allergen extracts are
treated with glutaraldehyde resulting in cross-linked
proteins with reduced allergenicity, (also known as aller-
goïds) and hypoallergenicity can also be induced by
reduction/alkylation in allergen molecules containing
disulfide bridges. Here for the first time, we will apply
this concept to recombinant food allergens.
Fish
For the development of immunotherapy for fish allergy,
we will focus on the major allergen from carp (Cyprinus
carpio), the parvalbumin (Cyp c 1). Parvalbumins are
small, acidic calcium-binding buffer proteins found in
fast muscle of lower and higher vertebrates. They have
been identified as the major fish allergens [26]. Parval-
bumin is a 3 EF-hand calcium-binding protein. It has
remarkable stability to heating and digestion, which
explains why, despite cooking and exposure to the gas-
trointestinal tract, it can sensitise patients [29]. A wild-
type recombinant (r) and three hypoallergenic mutants
representing of Cyp c 1 have been developed by our
partner in Vienna [26,27]. Wild-type rCyp c 1 was
shown to be highly cross-reactive to other fish parvalbu-
mins like from cod, salmon and tuna, ensuring broad
coverage of fish allergies. For many patients IgE binding
was Ca2+-dependent; mutating the two functional Ca2
+-binding sites resulted in loss of most of the secondary
structure and hypoallergenicity in dot-blot-inhibition (n
= 4) and a ~100-fold reduction in biological activity in
basophil histamine release (BHR; n = 1) compared to
the wild-type recombinant protein. We are producing
and purifying the natural and wild-type rCyp c 1, the
hypoallergenic double mutant and a chemically modified
wild-type rCyp c 1 (so-called allergoïd, produced by glu-
taraldehyde treatment) for pre-clinical evaluation in
FAST (Figure 1).
Peach
For peach (Prunus persica) allergy, we focus on its major
allergen, the non-specific lipid transfer protein (LTP)
Pru p 3. LTPs have been identified as the culprit of
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severe fruit allergy mainly for fruit-allergic patients in
Mediterranean countries [30,31]. Sensitization is usually
caused by peach LTP and cross-reactivity between
highly homologous LTPs results in clustered fruit aller-
gies. 50-95% sequence identity commonly gives rise to
IgE cross-reactivity, however, not always leading to clini-
cal fruit allergy. Both apple and strawberry LTP (Mal d
3 and Fra a 3, respectively) are approximately 80%
homologous to peach LTP [32], but where apple allergy
is common among LTP-sensitized peach allergic
patients, strawberry allergy is not. Therefore, Fra a 3
may be a naturally occurring hypoallergen. For Pru p 3,
several charged surface-exposed amino acids in three
regions across the molecule have been proposed to play
a role in IgE binding [33,34]. The structure of LTP is
highly dependent on its four disulfide bridges. Mutation
of a single cysteine in each pair forming a disulfide
bridge has been shown to significantly reduce the aller-
genicity of the major Parietaria weed LTP, Par j 1 [35]
and very recently for Pru p 3 [28]. All in all, we are
using five different strategies to produce hypoallergenic
LTP for safe treatment of fruit allergy; we produce and
purify wild-type natural and rPru p 3 and rPru p 3-
mutants (surface-exposed amino acids and disulfide
bridges), chemically modified wild-type rPru p 3 (reduc-
tion/alkylation and glutaraldehyde treatment) and rFra a
3, all tested for hypoallergenicity. These constructs are
summarized in Figure 2.
All (hypo-)allergen preparations as described above are
physico-chemically characterized by far UV CD-spectro-
scopy, mass-spectrometry and size-exclusion chromato-
graphy/dynamic light scattering. Stability is tested and
hypoallergenicity is assessed in patients’ sera (n = 30,
selected as described below) with ImmunoCAP (CAP)-
inhibition and BHR. Furthermore the capacity of wild-
type molecules (recombinant and natural), mutants and
allergoïds, to stimulate T-cell proliferation (using
PBMCs from fish/fruit-allergic patients) and induce IgG
antibodies in rabbits and/or mice is assessed.
On the basis of these analyses, using a weight-of-evi-
dence approach, the most appropriate hypoallergenic but
still immunogenic molecule is selected for GMP produc-
tion, toxicity testing and subsequent clinical trials.
Clinical studies
In the consortium there are six participating clinical
centers in six countries: Odense (OUH, Denmark), Łódź
(MUL, Poland), Reykjavik (LSH, Iceland), Madrid
(HCSC, Spain), Athens (NKUA, Greece) and Rome (IDI,
Italy). These centers have been chosen on the basis of
their specific expertise in food allergy and DBPCFC and
their geographic background.
The methodology will be identical to those of the clinical
studies performed within the EU-funded integrated project
EuroPrevall [3] that were coordinated by the partner from
Madrid (including standardized case record forms (CRFs),
methods for skin prick testing (SPT) and double-blind pla-
cebo-controlled food challenges (DBPCFCs). From the
clinical studies of EuroPrevall, we have concluded that fish
allergy is observed across Europe but it is especially fre-
quent in Iceland, Spain, Greece, Italy and Poland. More-
over, the Danish groups have published studies with 30+
codfish allergic patients [36,37]. Peach allergy caused by
LTP is frequently found in Spain, Italy and Greece.
Together, these centers therefore provide the necessary
expertise and cover some of the most important areas for
fish and peach allergy in Europe. All clinical studies and
clinical trials will be performed with the approval of the
local ethics committees, and according to the national and
European regulations.
Allergic patients for evaluation of candidate allergen
molecules
Clinical centers will enroll fish (parvalbumin) and/or
peach (LTP) allergic patients. The aim is access to
Figure 1 Four different (hypo-)allergenic constructs are
proposed in developing a construct for fish SIT. A/B: n/r wild-
type Cyp c 1 and the Calcium-binding site double mutant as
described before [26,27], C: glutaraldehyde treated rCyp c 1
(involves covalent linking of free amino-groups, as shown).
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biological samples for the evaluation of hypoallergeni-
city and T-cell reactivity of parvalbumin- and LTP-
variants described in the previous section. In addition
the patients are screened for MHC II alleles to select
appropriate candidates for evaluating the relevance of
T-cell epitopes. For both fish and peach we aim at
inclusion of 30 patients, evenly spread over the rele-
vant clinical centers, respectively. The sample size has
been calculated on the basis of the expected reduction
in allergenicity of the candidate molecules.
Patients are recruited at the 6 clinical centers involved
in the project. Inclusion is based on age (between 12
and 65) and a convincing clinical history for fish or
peach, a positive SPT and DBPCFC with fish or peach,
and a positive serum IgE test to rCyp c 1 (in case of
fish) or rPru p 3 (in case of peach). Patients with severe
anaphylaxis are excluded from DBPCFC to establish
their current reactivity to the foods. They will be
included in the clinical trials.
Phase I/IIa clinical trials
Phase I/IIa clinical trials using hypoallergenic recombi-
nant fish parvalbumin or peach LTP will be carried
out in Denmark and Spain, respectively. The main
objectives of the Phase I/IIa trials will be dose-finding
and to assess safety and pharmaco-dynamics. Safety
will be assessed with a careful recording of all adverse
events and adverse reactions. For pharmaco-dynamics
allergen-specific IgE, IgG/G4, IgA and T-cell prolifera-
tive responses will be monitored. Adult subjects aller-
gic to fish parvalbumin and to peach LTP recruited by
the above mentioned clinical partners will be invited to
participate. 24 individuals with a proportion active:pla-
cebo of 3:1 will be included for DBPCFC. The hypoal-
lergens will be tested in subgroups of patients at
different dosing schemes for 3 months in a staggered
manner at intervals of 2 weeks to allow for intermit-
tent safety reviews.
Phase IIb clinical trials
If no major side-effects are reported in Phase I/IIa trials,
Phase IIb trials will be performed. Patients will be
recruited according to the inclusion limits described
above. The studies will be randomized, double-blind pla-
cebo controlled (DBPC), with a proportion of active and
placebo treatments of 2:1.
The primary outcome of Phase IIb trial is the response
to DBPCFC performed after the treatment that will be
compared to the pretreatment challenge by survival ana-
lysis. The estimated total number of patients needed is
105 per trial, 70 active and 35 placebo subjects. For fish
this means that 12 active and 6 placebo subjects should
be recruited in each clinical center (total number 108),
and for fruit the respective figures will be 24 active and
12 placebo per center (total 108). Treatment at mainte-
nance dose will last for 6 months (monthly injections).
Safety and tolerability will be assessed by careful
recording of adverse events. Investigators will evaluate
the nature and severity of the events, in attempt to
determine the causal relationship with the immunother-
apy. Registry and classification of adverse events will be
performed in accordance with local regulations. The pri-
mary outcome of efficacy in the Phase IIb trials will be
the response to the intake of fish or peach assessed by a
standardized DBPCFC that will be performed before the
start of the treatment and at the end of it. DBPCFC per-
formed after the treatment will be compared to the pre-
treatment challenge by survival analysis. Secondary
outcomes of efficacy will be changes in SPT reactivity
(to a fish/peach extract), in specific IgE, IgA and IgG4
(to the respective purified allergen) in biological activity
of IgE (BHR) and in T-cell reactivity.
Immunology
For adequate monitoring and future improvement of
immunotherapy for food allergy, it is necessary to estab-
lish which immune mechanisms are protective. First,
Figure 2 Seven different (hypo-)allergenic constructs are proposed in developing a construct for peach SIT. wt and rPru p 3 (sequence
shown), a “natural hypoallergenic” rFra a 3 (changes in sequence compared to Pru p 3 are underlined), rPru p 3 sur: a surface mutant (3 amino
acids mutated to Alanin), rPru p 3 cys: 4 cysteines mutated to serine, rPru p 3 G: glutaraldehyde treated rPru p 3 (involves free amino-groups,
indicated), rPru p 3 RA: reduced and alkylated rPru p 3 (involves all cysteines). The known IgE-binding sites of Pru p 3 are boxed, H1-4 indicate
the a-helices.
Zuidmeer-Jongejan et al. Clinical and Translational Allergy 2012, 2:5
http://www.ctajournal.com/content/2/1/5
Page 5 of 9
this will be studied in a mouse model of food allergy
immunotherapy. Later, comprehensive immunological
studies during Phase IIb clinical trials will be carried out.
Immunotherapy with hypoallergens in a mouse model
A model of food hypersensitivity, first described by
Hugh Sampson et al. [38] is used to evaluate the poten-
tial of hypoallergens to treat mice sensitized with puri-
fied nCyp c 1 or nPru p 3. In this model, C3H/HeJ mice
are orally sensitized by repeated intra-gastric administra-
tion of allergen in combination with cholera toxin as
adjuvant, followed by challenge with a single large dose
of allergen to provoke an allergic reaction. The charac-
terization of the allergic responses is based on well-
established in vivo parameters (symptomatic scoring,
vascular leakage and immediate type skin tests) and in
vitro tests (measurement of allergen-specific immuno-
globulin in serum and mucosal secretions (ELISA), cel-
lular responses in spleen and lymph node cells (T cell
proliferation and cytokine secretion assays), plasma his-
tamine levels and histological tests (intestine and lung
sections). Pilot experiments using varied feeding proto-
cols and different antigen concentrations are performed
to establish an optimal sensitization (characterized by
highest production of IgE) and challenge regime. The
latter will be important also to elaborate a symptomatic
scoring system that can be used to confirm the benefits
of the treatments being proposed.
The model will be used to assess both subcutaneous
immunotherapy with the selected hypoallergenic parval-
bumin and lipid transfer proteins. Apart from evaluation
of these candidate molecules for human trials, the
mouse model is used to investigate the immune
mechanisms of subcutaneous immunotherapy for food
allergy. All animal experiments are carried out according
to national and European regulations.
Changes in immune response during immunotherapy
As outlined in the introduction, the immune mechanism
of allergen-specific immunotherapy has only been stu-
died in some detail for treatment of respiratory allergies
[5,6] and to a lesser extent, bee venom allergy [7]. For
the treatment of food allergy, only a limited number of
well-designed immunotherapy studies (two SIT studies
for peanut [16,17] and two SLIT studies for hazelnut
and peach, respectively [20,21,23] have been performed,
without detailed mechanistic studies. Immunological
investigations were limited to IgE and IgG serology. In
this project, we aim to treat with the major active com-
pound only and also monitor serum antibodies to this
major allergen. This will establish whether there is a
correlation between efficacy and IgG and IgA responses
to the active compound.
Additionally we will study what exactly happens to
allergen-specific IgE. Rise and fall of IgE-titers and
changes in specificity will be studied. Additionally, it is
important to investigate what causes the inhibition of
early and late-phase reactions in the presence of rela-
tively stable IgE titers; is it qualitative changes in IgE
(which will be monitored by measuring biological activ-
ity in histamine release tests) or potentially blocking
effects of IgG and/or IgA antibodies.
The number of clinical trials where allergen-specific
T-cell responses were monitored and characterized in
detail is very limited. In order to adequately monitor
and improve efficacy of food allergy SCIT, it is essential
to acquire in depth knowledge on the mechanism. To
establish the role of different Th-cell subsets in the
mechanism of protection induced by immunotherapy,
blood samples will be obtained prior to, during and
after completion of therapy to analyze T-cell prolifera-
tion (FACS analysis), cytokine production (Luminex/
ELISPOT/ELISA) and surface marker expression (FACS
analysis) to determine the phenotype of allergen-specific
T-cells. To be able to selectively focus at allergen-speci-
fic T-cells, food-allergen-specific tetramer (or ultimer)
reagents will also be developed (see below).
With all these studies we can further elucidate the
immune mechanism of allergen-specific immunotherapy
and hopefully identify useful (early) biomarkers for
efficacy.
T-cell epitopes of parvalbumin and LTP
To be able to study the phenotype of allergen-specific
T-cells in healthy and allergic subjects and follow
changes in phenotype during SCIT, parvalbumin- and
LTP specific MHC class II (MHC II) tetramers will be
developed. Essentially, there are two unknowns: 1)
which MHC II molecules are most relevant for antigen
presentation in case of parvalbumin and LTP 2) which
T-cell epitopes play a dominant role in parvalbumin-
and LTP-specific T-cell responses? Since the beginning
of the FAST project, three papers have addressed the
latter question for peach LTP [39-41] all pointing to the
regions Pru p 312-27 and Pru p 357-80 as carrying impor-
tant T-cell epitopes. Immuno-purified MHC II mole-
cules covering a large part of the Caucasian population
(twelve different HLA-DR and HLA-DP4 molecules) will
be used to perform binding studies with overlapping
peptides spanning the sequence of Cyp c 1 and Pru p 3
using the HLA express system [42]. Affinity of binding
to MHC II, the capacity to stimulate T-cells, and the
prevalence of the particular MHC II molecule among
Europeans and their availability for production as tetra-
mers will decide which T-cell epitopes will be custom-
ordered. The aim is to have sufficient (HLA-) coverage
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to be able to study differences between healthy and
allergic T-cell responses and changes during immu-
notherapy. This will provide the tools to identify and
characterize parvalbumin- and LTP-specific T-cells at
epitope level.
Concluding remarks
The FAST project will increase our understanding on
how to bring the treatment of food allergy to a higher
level, i.e. by adding an alternative to the spectrum of
treatment modalities for food allergy that is currently
restricted to avoidance and rescue medication, and SLIT
or OIT. Overall, allergy is recognized as a major disease
affecting around 30-40% of the population. Food allergy
is estimated to affect about 5% of the population, but
additionally it also is a major disease because of its great
impact on the quality of life. Food allergy is potentially
life-threatening and the risk of accidental intake causes
great fear and ultimately leads to social isolation. The
FAST project aims at significantly lowering thresholds
and consequently improving quality of life of food
allergy sufferers.
FAST investigates the development of novel therapies
for the treatment of food allergy by combining the prin-
ciples of traditional allergen-specific immunotherapy
with biotechnology (hypoallergenic recombinant aller-
gens). Standardization of allergen extracts has been a
major challenge over the past decades. The introduction
of highly purified products will end the situation where
standardization of variable biological products puts an
increasing burden on quality control departments and
regulatory authorities.
The research proposed in FAST aims at the develop-
ment of treatment for diseases that start in early child-
hood, using top clinical, biotechnological and
immunological research. The strategy chosen will not
involve children up to the stage of Phase IIb clinical
trials. Phase I/IIa clinical trials will be carried out in
adults only. Moreover, children enrolled in Phase IIb
clinical trials will not be under 12. FAST aims to
develop a novel therapy for food allergy that will have a
positive impact on the diet of food allergic patients
improve their quality of life, allowing them to stop
avoiding fish and fruit which are important components
of a healthy “non-obese” diet.
Once more the importance of child health is
addressed. As mentioned food allergy is a disease that in
most cases starts in very young children. The FAST pro-
ject aims to develop a therapy for food allergy that in
the future can also be safely used in children.
Obviously, the approach chosen by FAST is applicable
to the treatment of other food but also respiratory aller-
gies. Moreover, successful therapy is the first step
towards allergen-specific preventive immunotherapy or
vaccination. FAST targets a chronic disease that is
potentially life-threatening by anaphylactic shock. Food
allergy is currently untreatable, avoidance being the only
remedy. It will do so by using the established (subcuta-
neous) route of administration. It will use established
(chemical modification) and emerging (mutants) meth-
ods to achieve hypoallergenicity, aiming at increased
safety of the treatment. It aims at replacing extracts by
highly purified recombinant allergens. This will allow
more accurate administration of active ingredients,
which will hopefully improve efficacy. The mechanism
of action will be investigated with a major focus on the
potential role of allergen-specific regulatory T-cell. To
be really able to study these cells at the level of specific
epitopes, food allergen specific tetramers will be devel-
oped. Overall, the project aims at developing a novel
strategy to replace avoidance and rescue medications as
the only way to treat food allergy: allergen-specific
immunotherapy with biotech hypoallergens.
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